Depression‐resistant endophenotype in mice overexpressing cannabinoid CB2 receptors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  British Journal of Pharmacology

• Publication date

  2010-08-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1111/j.1476-5381.2010.00819.xPMID 20649579PMCID PMC2936848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The neurobiology of depression.

  2012cited by this paper
• The future of endocannabinoid-oriented clinical research after CB1 antagonists

  2009cited by this paper
• Emerging strategies for exploiting cannabinoid receptor agonists as medicines

  2009cited by this paper
• Altered CB1 receptor‐signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine

  2009cited by this paper
• Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.

  2009cited by this paper
• Activation of endocannabinoid transmission induces antidepressant-like effects in rats.

  2008cited by this paper
• Guide to Receptors and Channels (GRAC), 3rd edition

  2008cited by this paper
• Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses.

  2008cited by this paper
• The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets

  2008cited by this paper
• Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects

  2008influential reference
• Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders.

  2008cited by this paper
• Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment

  2008cited by this paper
• Crucial Role of CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic Pain

  2008cited by this paper
• Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists

  2008cited by this paper
• Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.

  2008cited by this paper
• CB2 receptors in the brain: role in central immune function

  2008cited by this paper
• Age‐dependent effects of chronic stress on brain plasticity and depressive behavior

  2008cited by this paper
• Chronic mild stress impairs cognition in mice: from brain homeostasis to behavior.

  2008cited by this paper
• Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal.

  2008cited by this paper
• Interferon-γ Is a Critical Modulator of CB2 Cannabinoid Receptor Signaling during Neuropathic Pain

  2008cited by this paper
• Neuropsychobiological Evidence for the Functional Presence and Expression of Cannabinoid CB2 Receptors in the Brain

  2007cited by this paper
• Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms.

  2007cited by this paper
• Cannabinoid CB2 receptors: immunohistochemical localization in rat brain.

  2006cited by this paper
• Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression.

  2006cited by this paper
• Metabotropic Glutamate Receptor Subtype 7 Ablation Causes Dysregulation of the HPA Axis and Increases Hippocampal BDNF Protein Levels: Implications for Stress-Related Psychiatric Disorders

  2006cited by this paper
• Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper.

  2006cited by this paper
• Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.

  2005cited by this paper
• The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats

  2005cited by this paper
• A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.

  2005cited by this paper
• Susceptibility to subchronic unpredictable stress is related to individual reactivity to threat stimuli in mice.

  2004cited by this paper
• BMC Neurology BioMed Central

  2004cited by this paper
• The effects of chronic antidepressant treatment in an animal model of anxiety

  2004cited by this paper
• Role of Endocannabinoids and Cannabinoid CB1 Receptors in Alcohol‐Related Behaviors

  2004cited by this paper
• Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment.

  2004cited by this paper
• Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims

  2004cited by this paper
• The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels.

  2004cited by this paper
• Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice

  2003cited by this paper
• MinireviewFinding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments

  2003cited by this paper
• The mouse brain in stereotaxic coordinates

  2003cited by this paper
• The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

  2003cited by this paper
• Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

  2003cited by this paper
• Leukemic predisposition of pSca-1/Cb2 transgenic mice.

  2002cited by this paper
• Assessing antidepressant activity in rodents: recent developments and future needs.

  2002cited by this paper
• Preclinical models: status of basic research in depression.

  2002cited by this paper
• Antagonist-induced micro-opioid receptor up-regulation decreases G-protein receptor kinase-2 and dynamin-2 abundance in mouse spinal cord.

  2002cited by this paper
• Neurobiology of depression.

  2002cited by this paper
• Antagonist-induced μ-opioid receptor up-regulation decreases G-protein receptor kinase-2 and dynamin-2 abundance in mouse spinal cord

  2002cited by this paper
• The cellular neurobiology of depression

  2001cited by this paper
• The Mouse Brain in Stereotaxic Coordinates

  2001cited by this paper
• Control of the cell survival/death decision by cannabinoids

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Neurotrophins: roles in neuronal development and function.

  2001cited by this paper
• Regional expression of a gene encoding a neuron-specific Na(+)-dependent inorganic phosphate cotransporter (DNPI) in the rat forebrain.

  2000cited by this paper
• 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity.

  2000cited by this paper
• Altered fear circuits in 5-HT(1A) receptor KO mice.

  2000cited by this paper
• AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.

  1997cited by this paper
• Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation

  1997cited by this paper
• Individual differences in response to imipramine in the mouse tail suspension test

  1997cited by this paper
• Chronic mild stress and sucrose consumption: validity as a model of depression.

  1996cited by this paper
• Hippocampal atrophy in recurrent major depression.

  1996cited by this paper
• Pharmacological validation of the chronic mild stress model of depression.

  1996cited by this paper
• Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

  1995cited by this paper
• AM630, a competitive cannabinoid receptor antagonist.

  1995cited by this paper
• Effects of chronic mild stress on performance in behavioural tests relevant to anxiety and depression.

  1994cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• AN ANIMAL MODEL OF ANHEDONIA

  1992cited by this paper
• Chronic mild stress-induced anhedonia: a realistic animal model of depression.

  1992cited by this paper
• Up-regulation of opiate receptors following chronic naloxone treatment in aged rats.

  1989cited by this paper
• [23] Punch sampling biopsy technique

  1983cited by this paper
• Punch sampling biopsy technique.

  1983cited by this paper
• Depression: a new animal model sensitive to antidepressant treatments

  1977cited by this paper
• Identification functional characterization of brainstem cannabinoid CB2 receptors.

  year unknowncited by this paper

• Increased risk of suicide in substance use disorder: a neurobiological perspective

  2026cites this paper
• Inhibition of fatty acid binding protein 5 prevents stress-induced anxiogenic and depressive-like symptoms through modulation of hippocampal neurogenesis, cannabinoid and neurotrophic signaling in the limbic circuitry.

  2025cites this paper
• Aframomum melegueta Seed Extract’s Effects on Anxiety, Stress, Mood, and Sleep: A Randomized, Double-Blind, Pilot Clinical Trial

  2025cites this paper
• A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders.

  2025cites this paper
• Research progress regarding endocannabinoid system involvement in pain modulation and electroacupuncture analgesia

  2025cites this paper
• Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study.

  2025cites this paper
• Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer’s disease through CB1 activation and inflammation modulation

  2025cites this paper
• Role of CB2 cannabinoid receptors in the ameliorative effects of curcumin on BCG-induced depression in mice: Insights into peripheral inflammation and central NF-κB signaling

  2025cites this paper
• Characterization of Novel and Known Activators of Cannabinoid Receptor Subtype 2 Reveals Mixed Pharmacology That Differentiates Mycophenolate Mofetil and GW-842,166X from MDA7

  2025cites this paper
• MCH11, a new monoacylglycerol lipase inhibitor, reduces ethanol consumption and motivation to drink in mice, with sex-dependent differences.

  2025cites this paper
• The CB2 Receptor in Immune Regulation and Disease: Genetic Architecture, Epigenetic Control, and Emerging Therapeutic Strategies

  2025cites this paper
• PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders

  2025cites this paper
• Cannabinoid for alcohol use disorder.

  2024cites this paper
• Brain region specific regulation of anandamide (down) and sphingosine-1-phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress

  2024cites this paper
• Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders

  2024cites this paper
• The cannabinoid CB2 agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats.

  2024cites this paper
• CB2 receptor in the CNS: from immune and neuronal modulation to behavior.

  2023cites this paper
• Cannabinoid type 2 receptor inhibition enhances the antidepressant and proneurogenic effects of physical exercise after chronic stress

  2023cites this paper
• Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviours

  2023cites this paper
• Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model

  2023cites this paper
• Endocannabinoid administration affects taste preference and the expression of cannabinoid and opioid receptors in the amygdala of early lactating cows

  2023cites this paper
• Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles

  2023cites this paper
• Role of CB2 cannabinoid receptor in the development of food addiction in male mice.

  2023cites this paper
• Regulation of Cortico-Thalamic JNK1/2 and ERK1/2 MAPKs and Apoptosis-Related Signaling Pathways in PDYN Gene-Deficient Mice Following Acute and Chronic Mild Stress

  2023cites this paper
• Cannabidiol repairs behavioral and brain disturbances in a model of fetal alcohol spectrum disorder.

  2023cites this paper
• Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviors: effects of in vitro cannabidiol administration.

  2023cites this paper
• Molecular Changes Associated with Suicide

  2023cites this paper
• Neuroinflammation in the Central Nervous System: Exploring the Evolving Influence of Endocannabinoid System

  2023cites this paper
• A mouse model of the 3-hit effects of stress: Genotype controls the effects of life adversities in females.

  2023cites this paper
• Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders

  2023cites this paper
• G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

  2023cites this paper
• Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex.

  2022cites this paper
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders

  2022influential citation
• Spontaneous Activity of CB2 Receptors Attenuates Stress-Induced Behavioral and Neuroplastic Deficits in Male Mice

  2022cites this paper
• Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects.

  2022cites this paper
• Impact of the Cannabinoid System in Alzheimer's Disease

  2022cites this paper
• Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors

  2022cites this paper
• Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia

  2022cites this paper
• Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  2022influential citation
• Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice

  2022cites this paper
• Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders

  2022influential citation
• The Endocannabinoid 2-Arachidonoylglycerol Bidirectionally Modulates Acute and Protracted Effects of Predator Odor Exposure.

  2022cites this paper
• Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  2022cites this paper
• Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies

  2022cites this paper
• Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy.

  2022cites this paper
• A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

  2022cites this paper
• Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder

  2022cites this paper
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders

  2022influential citation
• The antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a preclinical systematic review and meta-analysis

  2022cites this paper
• The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder

  2021cites this paper
• Lipid endocannabinoids in energy metabolism, stress and developmental programming.

  2021cites this paper
• CB2 Receptor Involvement in the Treatment of Substance Use Disorders

  2021cites this paper
• Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry

  2021cites this paper
• The CB2 cannabinoid receptor as a therapeutic target in the central nervous system

  2021cites this paper
• The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder: A case–control association study

  2021cites this paper
• Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.

  2021cites this paper
• The Effects of Cannabinoids on Stress-Coping Behaviors and Neuroendocrinological Measures in Chronic Unpredtictable Stress: A Preclinical Systematic Review and Meta-Analysis

  2021influential citation
• Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice

  2021cites this paper
• Cannabidiol and Sertraline Regulate Behavioral and Brain Gene Expression Alterations in an Animal Model of PTSD

  2021cites this paper
• Molecular Targets of Cannabinoids Associated with Depression.

  2021cites this paper
• The Endocannabinoidome in Neuropsychiatry: Opportunities and Potential Risks.

  2021cites this paper
• Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.

  2021cites this paper
• The link between cannabinoids and depression

  2021cites this paper
• Targeting 2‐arachidonoylglycerol signalling in the neurobiology and treatment of depression

  2021cites this paper
• The cannabinoid system and microglia in health and disease.

  2021cites this paper
• Chronic Inhibition of FAAH Reduces Depressive-Like Behavior and Improves Dentate Gyrus Proliferation after Chronic Unpredictable Stress Exposure

  2021cites this paper
• The administration of sertraline plus naltrexone reduces ethanol consumption and motivation in a long-lasting animal model of post-traumatic stress disorder.

  2021cites this paper
• Integrating Endocannabinoid Signalling In Depression

  2021cites this paper
• Regulation of cannabinoid CB1 and CB2 receptors, neuroprotective mTOR and pro-apoptotic JNK1/2 kinases in postmortem prefrontal cortex of subjects with major depressive disorder.

  2020cites this paper
• Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review.

  2020cites this paper
• Association of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder

  2020cites this paper
• Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies

  2020cites this paper
• Endocannabinoid System Components as Potential Biomarkers in Psychiatry

  2020cites this paper
• A systematic, integrative review of the effects of the endocannabinoid system on inflammation and neurogenesis in animal models of affective disorders.

  2020cites this paper
• FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1.

  2020cites this paper
• URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels

  2020cites this paper
• Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice.

  2020cites this paper
• Are CB2 Receptors a New Target for Schizophrenia Treatment?

  2020cites this paper
• Progress in brain cannabinoid CB2 receptor research: From genes to behavior

  2019cites this paper
• Mechanisms of cannabinoid CB2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area

  2019cites this paper
• Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology

  2019cites this paper
• The molecular and cellular mechanisms of depression: a focus on reward circuitry

  2019cites this paper
• Altered Swimming Behaviors in Zebrafish Larvae Lacking Cannabinoid Receptor 2

  2019cites this paper
• Alcohol-induced conditioned place preference is modulated by CB2 cannabinoid receptors and modifies levels of endocannabinoids in the mesocorticolimbic system.

  2019cites this paper
• A functional variant of CB2 receptor gene interacts with childhood trauma and FAAH gene on anxious and depressive phenotypes.

  2019cites this paper
• Treadmill Exercise Improves LPS-Induced Memory Impairments via Endocannabinoid Receptors and Cyclooxygenase Enzymes.

  2019cites this paper
• Antidepressant-like Effects of β-caryophyllene on Restraint Plus Stress-induced Depression.

  2019cites this paper
• Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.

  2019cites this paper
• Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system.

  2019cites this paper
• Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims

  2018cites this paper
• Treatment of anorexia nervosa with palmitoylethanoamide.

  2018cites this paper
• Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice

  2018cites this paper
• Role of the endocannabinoid system in drug addiction.

  2018cites this paper
• Pharmacological regulation of cannabinoid CB2 receptor modulates the reinforcing and motivational actions of ethanol

  2018cites this paper
• Endocannabinoid system, stress and HPA axis.

  2018cites this paper
• Effects of cannabidiol plus naltrexone on motivation and ethanol consumption

  2018cites this paper
• The Endogenous Cannabinoid System: A Cadre of Potential Therapeutic Targets

  2018cites this paper
• Cannabidiol reduces ethanol consumption, motivation and relapse in mice

  2018cites this paper
• Radix Polygalae Extract Attenuates PTSD-like Symptoms in a Mouse Model of Single Prolonged Stress and Conditioned Fear Possibly by Reversing BAG1

  2018cites this paper
• Deletion of Dlk1 increases the vulnerability to developing anxiety‐like behaviors and ethanol consumption in mice

  2018cites this paper